Jazz Pharmaceuticals plc
NASDAQ:JAZZBiotechnology
+$0.05 today
- Market cap
- $15.90B
- Beta
- 0.33
- P/E (TTM)
- 476.3
- EPS (TTM)
- $0.48
Volume 0.72M
Average 0.92M
JAZZ EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Jazz Pharmaceuticals plcNASDAQ: JAZZ
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA turns negative
Q3 FY2026 EBITDA was -$413.4M, compared with $235.86M a year earlier. Trailing-twelve-month EBITDA was $990.56M. Over 3 fiscal years it compounded at -43.7% a year.
Context
- EBITDA amounted to 6.2% of revenue in FY2025, down 31.2 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 16 analysts of $2.08B (+693.3%) for the fiscal year ending Dec 2026, a step up from the -82.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$413.4M-196.8% QoQ
- Last fiscal yearDec 2025
- $262.76M-82.7% YoY
- LTMSep 2026
- $990.56M+284.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -275.3% | +76.7% | +352.0 pp |
| 1 year | -82.7% | +693.3% | +776.0 pp |
| 3-year CAGR | -43.7% | +125.4% | +169.0 pp |
| 5-year CAGR | +64.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 262.76M USD
- Year-over-year change
- -82.7%
- 4-year CAGR
- -28.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 262.76M | -82.7% |
| FY2024 | 2024-12-31 | 1.52B | +5.0% |
| FY2023 | 2023-12-31 | 1.45B | -1.3% |
| FY2022 | 2022-12-31 | 1.47B | +42.9% |
| FY2021 | 2021-12-31 | 1.03B | — |
EBITDA vs competitors
How JAZZ compares with its peers on the latest reported figures
- JAZZ's LTM Sep 2026 EBITDA of $990.56M is the 3rd highest of the 9 companies compared; the peer median is $275.21M.
- Its year-over-year change of +284.7% is the 2nd highest of 8, against a peer median of +52.6%.
- EBITDA amounts to 21.0% of revenue for JAZZ, versus a peer median of 29.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.07B | +52.6% | +43.2% | 35.5% | |
| LTM Jun 2026 | $1.22B | — | -43.3% | 29.5% | |
| LTM Sep 2026 | $990.56M | +284.7% | -43.7% | 21.0% | |
| LTM Sep 2026 | $949.9M | +39.8% | +41.2% | 25.7% | |
| LTM Jun 2026 | $276.39M | +4.3% | +20.2% | 28.8% | |
| LTM Jun 2026 | $274.03M | +696.5% | +33.4% | 94.3% | |
| LTM Sep 2026 | $191.33M | +66.0% | — | 21.3% | |
| LTM Sep 2026 | $99.55M | +154.3% | — | 7.3% | |
| LTM Mar 2026 | -$50.64M | -7.0% | — | 32.2% | |
| Peer median (excluding JAZZ) | $275.21M | +52.6% | +33.4% | 29.2% | |
Competitors are the stored peer set for JAZZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.09B | 3.66B | 3.83B | 4.07B | 4.27B |
| Cost of Revenue | 440.76M | 540.52M | 435.58M | 445.71M | 503.3M |
| Gross Profit | 2.65B | 3.12B | 3.4B | 3.62B | 3.76B |
| Gross Margin | 85.8% | 85.2% | 88.6% | 89.0% | 88.2% |
| Research & Development | 505.75M | 590.45M | 849.66M | 884M | 782.74M |
| Selling, General & Admin | 1.45B | 1.42B | 1.34B | 1.39B | 1.81B |
| Operating Expenses | 2.48B | 3.18B | 2.82B | 2.91B | 3.54B |
| Depreciation & Amortization | 552.48M | 629.47M | 638.7M | 660.07M | 696.3M |
| EBITDA | 1.03B | 1.47B | 1.45B | 1.52B | 262.76M |
| EBITDA Margin | 33.2% | 40.1% | 37.8% | 37.4% | 6.2% |
| Operating Income | 170.28M | (65.53M) | 578.58M | 716.63M | 224.42M |
| Operating Margin | 5.5% | -1.8% | 15.1% | 17.6% | 5.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 278.77M | 288.24M | 289.44M | 238.1M | 195.05M |
| Other Income / Expenses | (283.83M) | (317.18M) | (283.66M) | (247.94M) | (853.01M) |
| Income Before Tax | (113.55M) | (382.71M) | 294.92M | 468.69M | (628.59M) |
| Pre-Tax Margin | -3.7% | -10.5% | 7.7% | 11.5% | -14.7% |
| Income Tax Expense | 216.12M | (158.65M) | (119.91M) | (91.43M) | (272.44M) |
| Net Income | (328.95M) | (224.06M) | 414.83M | 560.12M | (356.15M) |
| Net Margin | -10.6% | -6.1% | 10.8% | 13.8% | -8.3% |
| EPS (Basic) | (5.51) | (3.58) | 6.55 | 9.06 | (5.84) |
| EPS (Diluted) | (5.51) | (3.58) | 6.10 | 8.65 | (5.84) |
| Weighted Avg Shares | 59.69M | 62.54M | 63.29M | 61.84M | 60.98M |
| Weighted Avg Shares (Diluted) | 59.69M | 62.54M | 72.07M | 66.01M | 60.98M |
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
Intrinsic Alpha fair value
Locked
Current Price
$247.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.